07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq:ARVN), a biotechnology company creating a new class of drugs based on targeted protein ...
News
- Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast ...
- Is It Time to Start Worrying About the Stock Market?
Medical device maker Boston Scientific Corp. up 43 percent this year, was down 3.51 precent today and biotech firm Alexion Pharmaceuticals fell 4.49 ...
- Initial public offerings scheduled to debut next week
Business: Principal biotech developing immunotherapies for solid tumors. Tencent Music Entertainment - Shenzhen, China, 82 million shares, priced ...
- Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event ...
The study results are being presented at the 2018 San Antonio Breast ... (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. ... KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL.
- Bb Biotech Ag Has Trimmed Its Regeneron Pharmaceuticals (REGN) Position; Oberweis Asset ...
Bb Biotech Ag decreased Regeneron Pharmaceuticals Inc. (REGN) stake by ... Bb Biotech Ag sold 10,000 shares as Regeneron Pharmaceuticals Inc. .... Energy for project at Joint Base San Antonio – Seeking Alpha” published on ...